Avertix is committed to advancing life-sustaining patient care and the long-term management of Advanced Cardiovascular Disease through innovation, clinical science, and collaboration. With FDA-approved labeling indicating the Guardian System is safe and effective, we’re dedicated to providing physicians, health systems, and allied health professionals with the Avertix Guardian to help advance the standard of patient care. Avertix’s Guardian™ is the first implantable, patient alerting system designed to warn patients to seek medical attention for Acute Coronary Syndrome (ACS), including silent heart attacks. Delays in treatment contribute to the high level of mortality and morbidity from heart attacks. Symptoms (such as chest pain) are a poor predictor of ACS events with less than 20% of patients presenting to the emergency room actually having a true positive ACS event and more than one-third of heart attacks having atypical or no symptoms.